Nevertheless, the observation that both SRB103 peptides achieved similar weight loss to liraglutide despite a less potent anorectic effect adds to the evidence that GLP-1R/GCGR co-agonism may be an effective method of treating obesity, potentially with reduced anorexia-associated nausea (although this was not tested directly in our study). Here, GCGR is linked to Anorexia.